Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Iressa Shows 30% Response Rate in Many Hospitals
March 24, 2003
- Health Minister, JMA President Exchange Views on TV
March 24, 2003
- Taking Public Comments on Medical Device GCP Started
March 24, 2003
- Korosho to Revise Priority NDA Review System around April
March 24, 2003
- Guidant Japan: Multi-link Penta Stent System
March 24, 2003
- Chuikyo Talks Will Initially Focus on Pricing of New Drugs
March 24, 2003
- DIAGNOSTIC NEWS IN BRIEF
March 24, 2003
- Korosho to Impose Tougher Conditions for GE Houses in Supplement Listing
March 24, 2003
- 20% Tax Deduction to Be Allowed for 8 Medical Devices Designed to Prevent Accidents
March 24, 2003
- WORD NEWS IN BRIEF
March 24, 2003
- Safety Assurance Activities of New Drug Organization Outlined
March 24, 2003
- Pollinosis Intensifying Competition in Market for Allergy Treatments
March 24, 2003
- JABP, JRCS Report Cost Breakdowns for Plasma Fraction Preparations
March 24, 2003
- e-Detailing Makes Drs Deepen Their Knowledge: ACNielsen Survey
March 24, 2003
- REGULATORY NEWS IN BRIEF
March 24, 2003
- Targeted Treatment Solutions Needed: IBM Business Consulting Report
March 24, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BREIF
March 24, 2003
- Industry FTC Outlines Stricter Measures to Prevent Code Violations
March 17, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 17, 2003
- Fukujin Aims at Group Sales of \1 Trillion in 2006
March 17, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…